Bio-Techne (TECH) Common Equity (2009 - 2026)

Bio-Techne's Common Equity history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Common Equity rose 3.33% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 3.33% YoY), while the FY2025 annual figure was $1.9 billion, down 7.25% from the prior year.
• Common Equity was $2.1 billion for Q1 2026 at Bio-Techne, up from $2.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 billion in Q3 2024 to a low of $1.7 billion in Q2 2022.
• Historically, Common Equity has averaged $1.9 billion across 5 years, with a median of $2.0 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Common Equity climbed 15.61% in 2023, then fell 8.08% in 2025.
• A 5-year view of Common Equity shows it stood at $1.8 billion in 2022, then grew by 7.47% to $2.0 billion in 2023, then gained by 5.85% to $2.1 billion in 2024, then declined by 3.25% to $2.0 billion in 2025, then gained by 3.7% to $2.1 billion in 2026.
• The last three Common Equity figures came in at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.